CCM
ELV icon

Callodine Capital Management’s Elevance Health ELV Stock Holding History

Callodine Capital Management’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,000
Closed -$7.39M – 55
2025
Q2 		$7.39M Buy
+19,000
New +$7.64M 0.77% 34
2024
Q1 		– Sell
-17,500
Closed -$8.25M – 41
2023
Q4 		$8.25M Buy
17,500
+1,500
+9% +$694K 2.17% 22
2023
Q3 		$6.97M Buy
+16,000
New +$7.26M 1.94% 24

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Callodine Capital Management's ELV Position: Q3 2025 in Review

Callodine Capital Management sold out of Elevance Health (ELV) in Q3 2025, closing a stake of 19,000 shares — an estimated $7.39M sold.

Callodine Capital Management first reported a position in ELV in Q3 2023 and held it in 3 quarters. The position peaked at $8.25M in Q4 2023. 1,510 funds tracked by Wall St. Rank hold ELV as of Q3 2025.

  • Callodine Capital Management reported no remaining Elevance Health position as of Q3 2025 after selling out during the quarter.
  • Callodine Capital Management sold 19,000 Elevance Health shares in Q3 2025, an estimated $7.39M.
  • Callodine Capital Management first reported a position in Elevance Health in Q3 2023 and held it in 3 quarters.
  • Callodine Capital Management's Elevance Health position peaked at $8.25M in Q4 2023.
  • 1,510 funds tracked by Wall St. Rank held Elevance Health as of Q3 2025.

Based on Callodine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.